2-isopropyl-2-aza-bicyclo[3.1.0]hexane | 60423-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-isopropyl-2-aza-bicyclo[3.1.0]hexane
• 英文别名: 2-Propan-2-yl-2-azabicyclo[3.1.0]hexane
• CAS: 60423-11-2
• 化学式: C₈H₁₅N
• 分子量: 125.214
• InChiKey: BWPRKCLQDWTFNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• CHEMICAL COMPOUNDS
  申请人：Campbell Leonie

  公开号：US20080171734A1

  公开（公告）日：2008-07-17

  The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R 1 , A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

  这项发明涉及一类新型化合物，其化学式为（I）或其盐：其中R1、A和HET-1如规范中所述，可能在通过葡萄糖激酶（GLK）介导的疾病或医疗状况的治疗或预防中有用，例如2型糖尿病。该发明还涉及包括所述化合物的药物组合物，使用所述化合物治疗由GLK介导的疾病的方法，以及制备化合物（I）的方法。
• 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
  申请人：Zhang Hui

  公开号：US20140179638A1

  公开（公告）日：2014-06-26

  The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R 2a , R 2b , R 3 , R 4a , R 4b , R 5 , R 6a , R 6b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , R 12 , R 13a and R 13b are each independently as defined in the description.

  本发明涉及由式(I)表示的9-氨甲基取代四环素化合物，或其药学上可接受的盐、前药、溶剂化合物或异构体，以及制备这些化合物的方法和包含其的药物组合物。本发明还涉及这些化合物在制备用于治疗和/或预防四环素药物敏感疾病的药物中的用途。其中，R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7、R8、R9a、R9b、R10、R11、R12、R13a和R13b各自独立地如描述中所定义。
• [EN] PYRIDINE DERIVATIVES AS KIF18A INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE EN TANT QU'INHIBITEURS DE KIF18A
  申请人：AMGEN INC

  公开号：WO2021026100A1

  公开（公告）日：2021-02-11

  Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

  化合物的酰胺类似物（公式（I））：如本文所定义，并其合成中间体，能够调节KIF18A蛋白，从而影响细胞周期和细胞增殖的过程，以治疗癌症和癌症相关疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与KIF18A活性相关的疾病状态的方法。
• HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES
  申请人：MCKERRECHER Darren

  公开号：US20090029905A1

  公开（公告）日：2009-01-29

  Compounds of formula (I) wherein R 1 , HET-1 and HET-2 are as described in the specification, and their salts and prodrugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

  式(I)中，R1、HET-1和HET-2的化合物，以及它们的盐和前药，是葡萄糖激酶（GLK）的激活剂，因此在治疗例如2型糖尿病方面非常有用。本文还描述了制备式(I)化合物的过程。